JP2016503067A5 - - Google Patents

Download PDF

Info

Publication number
JP2016503067A5
JP2016503067A5 JP2015549834A JP2015549834A JP2016503067A5 JP 2016503067 A5 JP2016503067 A5 JP 2016503067A5 JP 2015549834 A JP2015549834 A JP 2015549834A JP 2015549834 A JP2015549834 A JP 2015549834A JP 2016503067 A5 JP2016503067 A5 JP 2016503067A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
cdr
acid sequence
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015549834A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016503067A (ja
JP6449777B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/077264 external-priority patent/WO2014100740A1/en
Publication of JP2016503067A publication Critical patent/JP2016503067A/ja
Publication of JP2016503067A5 publication Critical patent/JP2016503067A5/ja
Application granted granted Critical
Publication of JP6449777B2 publication Critical patent/JP6449777B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015549834A 2012-12-21 2013-12-20 抗ntb−a抗体ならびに関連する組成物および方法 Expired - Fee Related JP6449777B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261745239P 2012-12-21 2012-12-21
US61/745,239 2012-12-21
PCT/US2013/077264 WO2014100740A1 (en) 2012-12-21 2013-12-20 Anti-ntb-a antibodies and related compositions and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018203019A Division JP6817674B2 (ja) 2012-12-21 2018-10-29 抗ntb−a抗体ならびに関連する組成物および方法

Publications (3)

Publication Number Publication Date
JP2016503067A JP2016503067A (ja) 2016-02-01
JP2016503067A5 true JP2016503067A5 (enExample) 2017-01-12
JP6449777B2 JP6449777B2 (ja) 2019-01-09

Family

ID=50979291

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015549834A Expired - Fee Related JP6449777B2 (ja) 2012-12-21 2013-12-20 抗ntb−a抗体ならびに関連する組成物および方法
JP2018203019A Expired - Fee Related JP6817674B2 (ja) 2012-12-21 2018-10-29 抗ntb−a抗体ならびに関連する組成物および方法
JP2019238780A Withdrawn JP2020055870A (ja) 2012-12-21 2019-12-27 抗ntb−a抗体ならびに関連する組成物および方法
JP2022038055A Withdrawn JP2022066565A (ja) 2012-12-21 2022-03-11 抗ntb-a抗体ならびに関連する組成物および方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2018203019A Expired - Fee Related JP6817674B2 (ja) 2012-12-21 2018-10-29 抗ntb−a抗体ならびに関連する組成物および方法
JP2019238780A Withdrawn JP2020055870A (ja) 2012-12-21 2019-12-27 抗ntb−a抗体ならびに関連する組成物および方法
JP2022038055A Withdrawn JP2022066565A (ja) 2012-12-21 2022-03-11 抗ntb-a抗体ならびに関連する組成物および方法

Country Status (10)

Country Link
US (4) US9708404B2 (enExample)
EP (1) EP2934585B1 (enExample)
JP (4) JP6449777B2 (enExample)
CN (2) CN107880126B (enExample)
AU (1) AU2013364043B2 (enExample)
CA (1) CA2893977C (enExample)
EA (1) EA031025B1 (enExample)
HK (1) HK1216850A1 (enExample)
IL (2) IL239211B (enExample)
WO (1) WO2014100740A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2185198B1 (en) * 2007-08-02 2015-01-14 Gilead Biologics, Inc. Lox and l0xl2 inhibitors and uses thereof
CA2893977C (en) 2012-12-21 2024-02-13 Seattle Genetics, Inc. Anti-ntb-a antibodies and related compositions and methods
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
JP2017534251A (ja) * 2014-09-09 2017-11-24 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム Agr2およびその受容体c4.4aに対する遮断モノクローナル抗体
KR20170068409A (ko) * 2014-09-16 2017-06-19 이즈 참 리미티드 항-egfr 항체 및 그의 용도
MX388698B (es) * 2014-09-30 2025-03-20 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Moleculas de enlace, especialmente anticuerpos, enlazadas a l1cam(cd171).
BR112017008945A2 (pt) 2014-10-31 2018-01-16 Abbvie Biotherapeutics Inc Anticorpos anti-cs1 e conjugados fármaco- anticorpo
AU2015358615B2 (en) 2014-12-04 2021-08-05 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute myeloid leukemia
HK1253242A1 (zh) 2015-05-20 2019-06-14 Janssen Biotech, Inc. 用於治疗轻链淀粉样变性及其它cd38阳性血液恶性肿瘤的抗cd38抗体
US20170044265A1 (en) * 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
PL3316909T3 (pl) * 2015-06-30 2023-11-20 Seagen Inc. Przeciwciała anty-ntb-a i powiązane kompozycje i sposoby
AU2016350717B2 (en) 2015-11-03 2023-08-10 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
JP2019527678A (ja) 2016-06-28 2019-10-03 ユーエムセー・ユトレヒト・ホールディング・ベー・フェー CD38に特異的に結合する抗体によるIgE媒介疾患の治療
KR20200079293A (ko) 2017-10-31 2020-07-02 얀센 바이오테크 인코포레이티드 고위험 다발성 골수종을 치료하는 방법
MX2020008415A (es) * 2018-02-13 2020-10-28 Prec Biologics Inc Metodos y composiciones que actuan de forma selectiva sobre linfocitos treg.
EP3994172A1 (en) 2019-07-03 2022-05-11 Oxford BioTherapeutics Ltd Antibodies and methods of use
KR20220079590A (ko) * 2019-10-04 2022-06-13 티에이이 라이프 사이언시스 Fc 돌연변이 및 부위-특이적인 접합 성질을 포함하는 항체 조성물
US20230092356A1 (en) 2019-12-06 2023-03-23 Thoas Fioretos Novel agents and uses thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5515508A (en) 1993-12-17 1996-05-07 Taligent, Inc. Client server system and method of operation including a dynamically configurable protocol stack
WO1996036361A1 (en) 1995-05-18 1996-11-21 The Regents Of The University Of Michigan Dna binding antibodies
MA24512A1 (fr) 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
WO2002024888A2 (en) 2000-09-01 2002-03-28 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2001053466A1 (en) 1999-12-23 2001-07-26 Hyseq, Inc. Methods and materials relating to semaphorin-like polypeptides and polynucleotides
EP1252333A4 (en) 2000-01-25 2005-01-05 Nuvelo Inc METHODS AND SUBSTANCES RELATING TO CD84-TYPE POLYPEPTIDES AND POLYNUCLEOTIDES
WO2003068935A2 (en) 2002-02-14 2003-08-21 Nuvelo, Inc. Methods of therapy and diagnosis
AU2001253362A1 (en) 2000-04-13 2001-10-30 Smith Kline Beecham Corporation Novel compounds
AU2001274888A1 (en) 2000-05-19 2001-12-03 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US6464770B1 (en) 2000-08-08 2002-10-15 Advanced Minerals Corporation Perlite products with controlled particle size distribution
US7795412B2 (en) 2000-09-15 2010-09-14 Genentech, Inc. Nucleic acids encoding PRO6308 polypeptides and related vectors and host cells
US20030180888A1 (en) 2000-11-03 2003-09-25 Millennium Pharmaceuticals, Inc. CD2000 and CD2001 molecules, and uses thereof
EP1223218A1 (en) 2000-11-03 2002-07-17 Millennium Pharmaceuticals, Inc. CD2000 and CD2001 molecules and uses thereof
US7892730B2 (en) 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer
JP2004533222A (ja) 2001-03-12 2004-11-04 インサイト・ゲノミックス・インコーポレイテッド 免疫グロブリンスーパーファミリータンパク質
CA2454185A1 (en) 2001-07-19 2003-01-30 Innate Pharma Ntb-a, a surface molecule involved in natural killer cells activity
MXPA04001986A (es) 2001-08-29 2004-06-07 Genentech Inc Composiciones y metodos para el tratamiento de enfermedades relacionadas a la inmunidad.
US20060194265A1 (en) 2001-10-23 2006-08-31 Morris David W Novel therapeutic targets in cancer
WO2004004649A2 (en) 2002-07-08 2004-01-15 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CA2802205C (en) 2002-07-31 2016-01-19 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
WO2004016733A2 (en) 2002-08-16 2004-02-26 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
CA2500521A1 (en) 2002-10-02 2004-09-23 Nuvelo, Inc. Novel nucleic acids and polypeptides
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CN103394083B (zh) 2003-11-06 2017-07-18 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
WO2005108415A2 (en) 2004-04-30 2005-11-17 Biogen Idec Ma Inc. Membrane associated molecules
BRPI0513959A (pt) 2004-07-30 2008-05-20 Rinat Neuroscience Corp anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
WO2007008848A2 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
ES2585357T3 (es) 2005-07-07 2016-10-05 Seattle Genetics, Inc. Compuestos de monometilvalina que tienen modificaciones de la cadena lateral de fenilalanina en el extremo C
EP1940470B1 (en) * 2005-09-26 2013-04-17 Medarex, Inc. Antibody-drug conjugates and their use
US7847067B2 (en) * 2006-08-28 2010-12-07 ARCA Biopharma Antibodies to NTB-A
WO2009043944A1 (es) * 2007-10-03 2009-04-09 Germans Boada, S.A. Cortadora manual de cerámica
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
LT2211904T (lt) 2007-10-19 2016-11-25 Seattle Genetics, Inc. Cd19 surišantys agentai ir jų panaudojimas
WO2010022737A1 (en) 2008-08-29 2010-03-04 Symphogen A/S Anti-cd5 antibodies
EP2336295B1 (en) * 2008-09-16 2018-01-24 Mitsui Chemicals, Inc. Method for producing lactic acid from plant-derived raw material, and lactic-acid-producing bacterium
CA2757237A1 (en) 2009-04-01 2010-10-14 Jane Elizabeth Clarkson Anti-il-23 immunoglobulins
JP5785941B2 (ja) 2009-06-17 2015-09-30 アッヴィ・バイオセラピューティクス・インコーポレイテッド 抗vegf抗体とその使用
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
US8303093B2 (en) * 2009-12-15 2012-11-06 Xerox Corporation Print head having a polymer layer to facilitate assembly of the print head
BR112012017696A2 (pt) 2010-01-18 2017-10-03 Novo Nordisk Healthcare Ag Purificação de fatores de coagulação de sangue
UA108227C2 (xx) * 2010-03-03 2015-04-10 Антигензв'язуючий білок
ES2757675T3 (es) 2010-04-15 2020-04-29 Progenics Pharm Inc Anticuerpos para el tratamiento de la infección y enfermedad asociada a Clostridium difficile
US9243057B2 (en) * 2010-08-31 2016-01-26 The Regents Of The University Of California Antibodies for botulinum neurotoxins
KR101398363B1 (ko) * 2010-11-17 2014-05-22 추가이 세이야쿠 가부시키가이샤 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
TWI664191B (zh) 2010-11-22 2019-07-01 天賜製藥公司 Nk細胞調節治療及治療血液惡性疾病之方法
AP2014007415A0 (en) 2011-07-11 2014-02-28 Glenmark Pharmaceuticals Sa Antibodies that bind to OX40 and their uses
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
CA2893977C (en) * 2012-12-21 2024-02-13 Seattle Genetics, Inc. Anti-ntb-a antibodies and related compositions and methods
ES2612918T3 (es) * 2013-07-10 2017-05-19 Miltenyi Biotec Gmbh Método para inducir la proliferación de células asesinas naturales por nanomatrices móviles
PL3316909T3 (pl) * 2015-06-30 2023-11-20 Seagen Inc. Przeciwciała anty-ntb-a i powiązane kompozycje i sposoby

Similar Documents

Publication Publication Date Title
JP2016503067A5 (enExample)
JP6526189B2 (ja) 抗pd−l1抗体並びにその治療及び診断のための使用
JP2016536020A5 (enExample)
JP2016538318A5 (enExample)
HRP20240924T1 (hr) Anti - sirpalpha antitijela
JP2021501162A5 (enExample)
IL266756A (en) Human monoclonal antibodies that bind to MASP 2 and suppress MASP-dependent complement activation, methods for their production and uses
JP2020513791A5 (enExample)
JP2018519263A5 (enExample)
JP2017534256A5 (enExample)
RU2017121327A (ru) Комбинированная терапия на основе активирующих т-клетки биспецифических антигенсвязывающих молекул против cd3 и фолатного рецептора 1 (folr1) и антагонистов, связывающихся с осью pd-1
JP2016512551A5 (enExample)
JP2015520758A5 (enExample)
JP2011046732A5 (enExample)
JP2020503260A5 (enExample)
RU2008149918A (ru) Антитела к nkg2a и их применения
JP2020504723A5 (enExample)
JP2015509947A5 (enExample)
PE20140848A1 (es) Anticuerpos monoclonales contra la proteina rgma y sus usos
JP2014533659A5 (enExample)
JP2016531915A5 (enExample)
JP2018513149A5 (enExample)
JP2017526370A5 (enExample)
JP2012070737A5 (enExample)
JP2015504306A5 (enExample)